VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q57012647 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010846.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q57012647‏
024 ‎‡a 0000-0002-6270-3065‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q57012647‏
100 0 ‎‡a Marco L Davila‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Marco L Davila‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's 4-1BB enhancement of CAR T function requires NF-κB and TRAFs‏
670 ‎‡a Author's Biology and clinical application of CAR T cells for B cell malignancies‏
670 ‎‡a Author's CAR models: next-generation CAR modifications for enhanced T-cell function‏
670 ‎‡a Author's CAR T cells find strength in polyfunction‏
670 ‎‡a Author's CAR T cells, immunologic and cellular therapies in hematologic malignancies‏
670 ‎‡a Author's CARs Move To the Fast Lane.‏
670 ‎‡a Author's CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.‏
670 ‎‡a Author's CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date‏
670 ‎‡a Author's CD28 co-stimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function‏
670 ‎‡a Author's Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?‏
670 ‎‡a Author's Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies‏
670 ‎‡a Author's Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells‏
670 ‎‡a Author's Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.‏
670 ‎‡a Author's Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer.‏
670 ‎‡a Author's Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality‏
670 ‎‡a Author's Is Disease-Specific Immunotherapy a Potential Reality for MDS?‏
670 ‎‡a Author's Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events‏
670 ‎‡a Author's Tumor Microenvironment composition and severe cytokine release syndrome (CRS) Influence Toxicity in Patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel‏
670 ‎‡a Author's VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/DNB|1245966138‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/7191163756445234480001‏
909 ‎‡a (orcid) 0000000262703065‏ ‎‡9 1‏
919 ‎‡a vdjserveracloudbasedanalysisportalanddatacommonsforimmunerepertoiresequencesandrearrangements‏ ‎‡A VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.‏ ‎‡9 1‏
919 ‎‡a tumormicroenvironmentcompositionandseverecytokinereleasesyndromecrsinfluencetoxicityinpatientswithlargebcelllymphomatreatedwithaxicabtageneciloleucel‏ ‎‡A Tumor Microenvironment composition and severe cytokine release syndrome (CRS) Influence Toxicity in Patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel‏ ‎‡9 1‏
919 ‎‡a societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmuneeffectorcellrelatedadverseevents‏ ‎‡A Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events‏ ‎‡9 1‏
919 ‎‡a isdiseasespecificimmunotherapyapotentialrealityformds‏ ‎‡A Is Disease-Specific Immunotherapy a Potential Reality for MDS?‏ ‎‡9 1‏
919 ‎‡a humaneffectorsofacuteandchronicgvhdoverexpresscd83andpredictmortality‏ ‎‡A Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality‏ ‎‡9 1‏
919 ‎‡a gammaretroviralproductionandtcelltransductiontogeneticallyretargetprimarytcellsagainstcancer‏ ‎‡A Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer.‏ ‎‡9 1‏
919 ‎‡a donorcd19cartcellsexertpotentgraftversuslymphomaactivitywithdiminishedgraftversushostactivity‏ ‎‡A Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.‏ ‎‡9 1‏
919 ‎‡a concurrenttherapyofchroniclymphocyticleukemiaandphiladelphiachromosomepositiveacutelymphoblasticleukemiautilizingcd19targetedcartcells‏ ‎‡A Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells‏ ‎‡9 1‏
919 ‎‡a concisereviewemergingprinciplesfromtheclinicalapplicationofchimericantigenreceptortcelltherapiesforbcellmalignancies‏ ‎‡A Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies‏ ‎‡9 1‏
919 ‎‡a chimericantigenreceptortherapyforchroniclymphocyticleukemiawhatarethechallenges‏ ‎‡A Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?‏ ‎‡9 1‏
919 ‎‡a cd28costimulatorydomaintargetedmutationsenhancechimericantigenreceptortcellfunction‏ ‎‡A CD28 co-stimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function‏ ‎‡9 1‏
919 ‎‡a cd19targetedtcellsforhematologicmalignanciesclinicalexperiencetodate‏ ‎‡A CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date‏ ‎‡9 1‏
919 ‎‡a cd19cartargetedtcellsinducelongtermremissionandbcellaplasiainanimmunocompetentmousemodelofbcellacutelymphoblasticleukemia‏ ‎‡A CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.‏ ‎‡9 1‏
919 ‎‡a carsmovetothefastlane‏ ‎‡A CARs Move To the Fast Lane.‏ ‎‡9 1‏
919 ‎‡a cartcellsimmunologicandcellulartherapiesinhematologicmalignancies‏ ‎‡A CAR T cells, immunologic and cellular therapies in hematologic malignancies‏ ‎‡9 1‏
919 ‎‡a cartcellsfindstrengthinpolyfunction‏ ‎‡A CAR T cells find strength in polyfunction‏ ‎‡9 1‏
919 ‎‡a carmodelsnextgenerationcarmodificationsforenhancedtcellfunction‏ ‎‡A CAR models: next-generation CAR modifications for enhanced T-cell function‏ ‎‡9 1‏
919 ‎‡a biologyandclinicalapplicationofcartcellsforbcellmalignancies‏ ‎‡A Biology and clinical application of CAR T cells for B cell malignancies‏ ‎‡9 1‏
919 ‎‡a 41bbenhancementofcartfunctionrequiresnfκbandtrafs‏ ‎‡A 4-1BB enhancement of CAR T function requires NF-κB and TRAFs‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 RERO|A009654611‏
996 ‎‡2 BNF|12501030‏
996 ‎‡2 DNB|1056236264‏
996 ‎‡2 SUDOC|154759856‏
996 ‎‡2 CAOONL|ncf10727004‏
996 ‎‡2 ISNI|0000000115452542‏
996 ‎‡2 ISNI|0000000089270517‏
996 ‎‡2 BNF|15024199‏
996 ‎‡2 ISNI|0000000032044420‏
996 ‎‡2 LC|n 93119313‏
996 ‎‡2 ISNI|000000003177830X‏
996 ‎‡2 LC|no2011023421‏
996 ‎‡2 SUDOC|240566602‏
996 ‎‡2 LC|no2015152933‏
996 ‎‡2 SUDOC|083927638‏
996 ‎‡2 SUDOC|034233946‏
996 ‎‡2 ISNI|0000000061058194‏
996 ‎‡2 BNCHL|10000000000000000018229‏
996 ‎‡2 LC|ns2015003191‏
996 ‎‡2 BLBNB|000274680‏
996 ‎‡2 RERO|A012023461‏
996 ‎‡2 LC|n 2006004091‏
996 ‎‡2 DNB|1261612868‏
996 ‎‡2 LC|n 86872434‏
996 ‎‡2 NUKAT|n 2015002286‏
996 ‎‡2 LC|no2005008743‏
996 ‎‡2 ISNI|0000000041611052‏
996 ‎‡2 DNB|1057427977‏
996 ‎‡2 LC|n 94052946‏
996 ‎‡2 DNB|1056435410‏
996 ‎‡2 ISNI|0000000048751883‏
996 ‎‡2 BNE|XX1008177‏
996 ‎‡2 BNC|981058515946406706‏
996 ‎‡2 LC|no2020105196‏
996 ‎‡2 ISNI|0000000443935500‏
996 ‎‡2 SUDOC|200541714‏
996 ‎‡2 CAOONL|ncf11890940‏
996 ‎‡2 CAOONL|ncf10687023‏
996 ‎‡2 CAOONL|ncf11417346‏
996 ‎‡2 BNE|XX1079231‏
996 ‎‡2 SUDOC|182025489‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Davila, Marco L.‏ ‎‡2 DNB|1245966138‏ ‎‡3 suggested‏ ‎‡3 standard number‏